Zentalis Pharmaceuticals Inc
zentalis.comZentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates targeting cancer. The company generates no product revenue, funding operations through equity and debt financing while advancing its pipeline toward regulatory approval. As of the 10-K filed March 26, 2026, Zentalis reported net cash used in operating activities of $125.2 million for the year ended December 31, 2025, down from $170.9 million in the year ended December 31, 2024. The lead candidate is azenosertib, a small molecule being evaluated in clinical trials, including in combination with other therapies. Zentalis has never declared or paid a cash dividend and does not anticipate doing so. Julie Eastland serves as President and Chief Executive Officer. The company has no credit facility or committed sources of capital and relies on capital markets to fund ongoing research and development.
Products & Services
Azenosertib, a small molecule drug candidate being evaluated in clinical trials for cancer indications, including in combination with other therapies. Additional pipeline candidates are referenced but not individually named in the available excerpts.
Revenue Model
Pre-revenue clinical-stage company. Operations are funded through equity issuances and potential future collaboration, licensing, or partnership arrangements. No product revenue has been reported in the excerpts from the 10-K filed March 26, 2026.
Customers & Markets
End market is oncology. Target prescribers are physicians treating cancer patients. No commercial products have been approved and no customer revenue is reported as of the 10-K filed March 26, 2026.
Geographic Exposure
Incorporated and headquartered in the United States. Clinical trials reference FDA and ex-U.S. regulatory authorities, indicating some international trial activity, but no specific geographic revenue breakdown is provided in the available excerpts.
Financial Snapshot
Loading...
